Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Crosses Below Two Hundred Day Moving Average – Here’s Why

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.76 and traded as low as $0.59. Karyopharm Therapeutics shares last traded at $0.62, with a volume of 791,301 shares.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on KPTI. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, January 15th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $3.00 target price on shares of Karyopharm Therapeutics in a research note on Monday, February 10th. Piper Sandler increased their price target on Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Finally, StockNews.com lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Karyopharm Therapeutics has an average rating of “Moderate Buy” and an average target price of $5.00.

Karyopharm Therapeutics Stock Down 4.8 %

The company’s 50 day moving average price is $0.67 and its 200-day moving average price is $0.76. The stock has a market cap of $75.71 million, a P/E ratio of -0.53 and a beta of 0.06.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Wednesday, February 19th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.02. Equities research analysts anticipate that Karyopharm Therapeutics Inc. will post -0.83 earnings per share for the current year.

Institutional Trading of Karyopharm Therapeutics

A number of large investors have recently bought and sold shares of KPTI. Velan Capital Investment Management LP acquired a new stake in Karyopharm Therapeutics during the fourth quarter worth approximately $27,000. Focus Partners Wealth acquired a new stake in shares of Karyopharm Therapeutics during the 4th quarter worth approximately $31,000. TD Waterhouse Canada Inc. acquired a new stake in shares of Karyopharm Therapeutics during the 4th quarter worth approximately $32,000. Two Sigma Advisers LP increased its stake in shares of Karyopharm Therapeutics by 145.5% in the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock valued at $52,000 after acquiring an additional 45,400 shares in the last quarter. Finally, Opti Capital Management LP bought a new position in Karyopharm Therapeutics during the fourth quarter worth $85,000. 66.44% of the stock is currently owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).